Evidence map›Paper›PMID 38335471›Full record

ArticleNeurology2024

Prognostic Role of Ventricular Size and Its Dynamics in Patients With Leptomeningeal Metastasis From Solid Tumors.

Emilie Le Rhun, Patrick Devos, Katharina Seystahl, Joost L M Jongen, Dorothee Gramatzki, Patrick Roth, Martin J Van Den Bent, Luca Regli, Dieta Brandsma, Michael Weller

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Emilie Le RhunFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0002-9408-3278
Patrick DevosFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0001-7803-9552
Katharina SeystahlFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0002-4072-5669
Joost L M JongenFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.
Dorothee GramatzkiFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.
Patrick RothFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0003-3897-214X
Martin J Van Den BentFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0001-5710-5127
Luca RegliFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0003-4639-4474
Dieta BrandsmaFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0001-7998-9904
Michael WellerFrom the Departments of Neurosurgery (E.L.R., L.R.) and Neurology (E.L.R., K.S., D.G., P.R., M.W.), University Hospital and University of Zurich, Switzerland; Lillometrics (P.D.), Univ. Lille - CHU Lille; Brain Tumor Center at Erasmus MC Cancer Institute (J.L.J., M.J.V.D.B.), Erasmus University Hospital Rotterdam, the Netherlands; and Department of Neuro-Oncology (D.B.), Netherlands Cancer Institute, Amsterdam.ORCID 0000-0002-1748-174X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesHydrocephalus is a common radiologic sign in patients with leptomeningeal metastasis (LM) from solid tumors which can be assessed using the Evans index (EI). Here, we explored the prognostic value of ventricular size in LM.

methodsWe identified patients with LM from solid tumors by chart review at 3 academic hospitals to explore the prognostic associations of the EI at diagnosis, first follow-up, and progression.

resultsWe included 113 patients. The median age was 58.3 years (interquartile range [IQR] 46.1-65.8), 41 patients (36%) were male, and 72 patients (64%) were female. The most frequent cancers were lung cancer (n = 39), breast cancer (n = 36), and melanoma (n = 23). The median EI at baseline was 0.28 (IQR 0.26-0.31); the EI value was 0.27 or more in 67 patients (59%) and 0.30 or more in 37 patients (33%). Among patients with MRI follow-up, the EI increased by 0.01 or more in 16 of 31 patients (52%), including 8 of 30 patients (30%) without and 10 of 17 patients (59%) with LM progression at first follow-up. At LM progression, an increase of EI of 0.01 or more was noted in 18 of 34 patients (53%). The median survival was 2.9 months (IQR 1-7.2). Patients with a baseline EI below 0.27 had a longer survival than those with an EI of 0.27 or more (5.3 months, IQR 2.4-10.8, vs 1.3 months, IQR 0.6-4.1) (HR 1.70, 95% CI 1.135-2.534, DISCUSSION: The EI at baseline is prognostic in LM. An increase of EI during follow-up may be associated with inferior LM progression-free survival. Independent validation cohorts with larger sample size and evaluation of confounding factors will help to better define the clinical utility of EI assessments in LM.

Indexed as

Breast NeoplasmsLung NeoplasmsMeningeal CarcinomatosisFemaleHumansMaleMiddle AgedPrognosisRetrospective Studies

Identifiers

PMID38335471
PMCPMC10834142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.